Scarica l'app Stockscreener
145.04
0.05%
0.175
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$144.87
Aprire:
$146.3
Volume 24 ore:
858.15K
Relative Volume:
0.60
Capitalizzazione di mercato:
$21.26B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
13.87
EPS:
10.46
Flusso di cassa netto:
$1.85B
1 W Prestazione:
-2.62%
1M Prestazione:
+6.64%
6M Prestazione:
+1.29%
1 anno Prestazione:
-26.65%
Intervallo 1D:
$143.37
$146.45
Intervallo di 1 settimana:
$141.12
$150.28
Portata 52W:
$110.03
$204.18
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
145.03 | 21.24B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
759.64 | 681.42B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
175.14 | 426.76B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
221.59 | 390.07B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.60 | 237.08B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
NVO
Novo Nordisk Adr
|
61.55 | 258.61B | 45.44B | 16.18B | 9.21B | 3.634 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M - GuruFocus
December 19th Options Now Available For Biogen (BIIB) - Nasdaq
Biogen acquires Lowell firm developing device meant replace the spinal tap - The Business Journals
Biogen to acquire Alcyone Therapeutics - The Pharma Letter
Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs - BioPharma Dive
Biogen Inc. entered into a definitive agreement to acquire All Assets of Alcyone Therapeutics, Inc. for $85 million. - MarketScreener
Biogen Gets EU Nod for First Postpartum Depression Drug - Yahoo Finance
Biogen to buy Massachusetts-based Alcyone Therapeutics (BIIB:NASDAQ) - Seeking Alpha
Biogen To Acquire Alcyone Therapeutics - Nasdaq
Biogen to Acquire Alcyone Therapeutics for Initial $85 million - MarketScreener
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Dru - GuruFocus
Biogen to acquire Alcyone Therapeutics for $85 million - Investing.com
Biogen to buy Alcyone Therapeutics, expanding drug delivery solutions for key products and pipeline - MarketScreener
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates - Biogen
Biogen’s Zurzuvae approved as first postpartum depression drug in Europe - Yahoo Finance
EC nod for Biogen’s PPD drug Zurzuvae - The Pharma Letter
EC approves Biogen’s ZURZUVAE as first oral treatment for postpartum depression - Investing.com Australia
MBB Public Markets I LLC Acquires Shares of 2,150 Biogen Inc. $BIIB - MarketBeat
34,000 Shares in Biogen Inc. $BIIB Purchased by Strs Ohio - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 23,427 Shares of Biogen Inc. $BIIB - MarketBeat
Jacobi Capital Management LLC Acquires 2,064 Shares of Biogen Inc. $BIIB - MarketBeat
Swedbank AB Has $29.84 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Pullback Watch: Can Biogen Inc. sustain its profitability2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - خودرو بانک
Aug PostEarnings: Can Biogen Inc outperform in the next rally2025 Major Catalysts & Precise Swing Trade Entry Alerts - خودرو بانک
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treat - GuruFocus
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Po - GuruFocus
Biogen receives European Commission approval for Zurzuvae - MarketScreener
Biogen gets EU nod for Zurzuvae to treat post-partum depression - MSN
Biogen Receives European Commission Approval for ZURZUVAE® to Treat Postpartum Depression - Quiver Quantitative
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe - Biogen
First-Ever Oral Postpartum Depression Treatment: Biogen's ZURZUVAE Gets EU Green Light for 14-Day Therapy - Stock Titan
Biogen (BIIB) Receives a Hold from J.P. Morgan - The Globe and Mail
Biogen Inc. $BIIB Shares Acquired by Woodline Partners LP - MarketBeat
United Services Automobile Association Purchases Shares of 3,604 Biogen Inc. $BIIB - MarketBeat
Voya Investment Management LLC Reduces Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Acadian Asset Management LLC Purchases 14,357 Shares of Biogen Inc. $BIIB - MarketBeat
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way - Yahoo Finance
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biogen Inc Azioni (BIIB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):